NZ594019A - Novel antibacterial agents for the treatment of gram positive infections - Google Patents

Novel antibacterial agents for the treatment of gram positive infections

Info

Publication number
NZ594019A
NZ594019A NZ594019A NZ59401909A NZ594019A NZ 594019 A NZ594019 A NZ 594019A NZ 594019 A NZ594019 A NZ 594019A NZ 59401909 A NZ59401909 A NZ 59401909A NZ 594019 A NZ594019 A NZ 594019A
Authority
NZ
New Zealand
Prior art keywords
compounds
antibacterial agents
treatment
gram positive
novel antibacterial
Prior art date
Application number
NZ594019A
Other languages
English (en)
Inventor
Chester A Metcalf
Original Assignee
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cubist Pharm Inc filed Critical Cubist Pharm Inc
Publication of NZ594019A publication Critical patent/NZ594019A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ594019A 2008-12-22 2009-12-18 Novel antibacterial agents for the treatment of gram positive infections NZ594019A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13987508P 2008-12-22 2008-12-22
PCT/US2009/068747 WO2010075215A1 (en) 2008-12-22 2009-12-18 Novel antibacterial agents for the treatment of gram positive infections

Publications (1)

Publication Number Publication Date
NZ594019A true NZ594019A (en) 2013-08-30

Family

ID=41718893

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ594019A NZ594019A (en) 2008-12-22 2009-12-18 Novel antibacterial agents for the treatment of gram positive infections

Country Status (26)

Country Link
US (3) US8507647B2 (enExample)
EP (2) EP2674437A1 (enExample)
JP (1) JP5670914B2 (enExample)
KR (1) KR101717795B1 (enExample)
CN (1) CN102325787B (enExample)
AR (1) AR074833A1 (enExample)
AU (1) AU2009330245C1 (enExample)
BR (1) BRPI0923567A2 (enExample)
CA (1) CA2747965C (enExample)
CY (1) CY1114883T1 (enExample)
DK (1) DK2379580T3 (enExample)
ES (1) ES2442167T3 (enExample)
HR (1) HRP20131170T1 (enExample)
IL (1) IL213638A0 (enExample)
MX (1) MX2011006803A (enExample)
NZ (1) NZ594019A (enExample)
PL (1) PL2379580T3 (enExample)
PT (1) PT2379580E (enExample)
RS (1) RS53152B (enExample)
RU (1) RU2512396C2 (enExample)
SG (1) SG172299A1 (enExample)
SI (1) SI2379580T1 (enExample)
SM (1) SMT201400037B (enExample)
TW (1) TWI444198B (enExample)
WO (1) WO2010075215A1 (enExample)
ZA (1) ZA201104693B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013157188A (ru) 2011-05-26 2015-07-10 Кьюбист Фармасьютикалз, Инк. Композиции св-183,315 и относящиеся к ним способы
US10377699B2 (en) * 2013-11-06 2019-08-13 The University Of Hong Kong Daptomycin analogues and a method for the preparation of daptomycin or a daptomycin analogue
WO2015172047A1 (en) * 2014-05-08 2015-11-12 Merck Sharp & Dohme Corp. Cyclic peptide compounds and related methods, salts and compositions
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
MX386103B (es) * 2016-04-22 2025-03-18 Astrazeneca Ab Inhibidores de mcl-1 y metodos de uso de los mismos.
US10098890B2 (en) 2016-10-29 2018-10-16 Cipla Limited Stable carfilzomib formulations
IT201600127655A1 (it) * 2016-12-16 2018-06-16 Gnosis Spa Processo per la purificazione di antibiotici lipopolipeptidici
US10072045B1 (en) 2017-06-26 2018-09-11 Ramapo Pharmaceuticals, Inc. Antibacterial lipopeptides and methods for their preparation and use
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof
RU2762182C1 (ru) * 2020-12-08 2021-12-16 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе" Гауземицины А и В - гликолипопептидные антибактериальные антибиотики и способ их получения

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
US4812470A (en) 1982-02-27 1989-03-14 Beecham Group P.L.C. Antibacterial monic acid derivatives
US4399067A (en) 1982-05-21 1983-08-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4396543A (en) * 1982-05-21 1983-08-02 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
IL68700A0 (en) * 1982-05-21 1983-09-30 Lilly Co Eli Improvements relating to a-21978c cyclic peptide derivatives and their production
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CS276978B6 (en) 1984-10-09 1992-11-18 Lilly Co Eli Process for preparing a-21978c antibiotic derivative
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
CA2043762C (en) 1990-06-07 2001-05-29 Adam J. Kreuzman Lipopeptide deacylase
AU7497594A (en) 1993-08-13 1995-03-14 Smithkline Beecham Plc Derivatives of monic acids a and c having antibacterial, antimycoplasmatical, antifungal and herbicidal activity
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
CA2248348C (en) 1996-03-08 2008-06-10 Fujisawa Pharmaceutical Co., Ltd. Process for the deacylation of cyclic lipopeptides
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
HK1040363B (en) 1998-09-25 2007-01-26 Cubist Pharmaceuticals Llc Use of daptomycin
JP2003520353A (ja) 1999-11-03 2003-07-02 ザ ウィタカー コーポレーション マルチファイバアレー用光電子モジュール
WO2001044271A2 (en) 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Daptomycin analogs and their use as antibacterial agents
KR20020063228A (ko) 1999-12-15 2002-08-01 큐비스트 파마슈티컬즈 인코포레이티드 항균제로서 리포펩티드
US6911525B2 (en) * 1999-12-15 2005-06-28 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
EP1423137B1 (en) 2001-08-06 2009-04-29 Cubist Pharmaceuticals, Inc. Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
EP1814588A2 (en) * 2004-11-12 2007-08-08 Cubist Pharmaceuticals, Inc. Antiinfective lipopeptides

Also Published As

Publication number Publication date
KR101717795B1 (ko) 2017-03-17
PT2379580E (pt) 2014-01-20
AU2009330245C1 (en) 2013-09-26
HRP20131170T1 (hr) 2014-01-03
JP2012513467A (ja) 2012-06-14
HK1161886A1 (en) 2012-08-10
SMT201400037B (it) 2014-05-07
EP2379580A1 (en) 2011-10-26
AR074833A1 (es) 2011-02-16
TW201028161A (en) 2010-08-01
EP2674437A1 (en) 2013-12-18
ZA201104693B (en) 2013-01-30
AU2009330245A1 (en) 2011-08-04
JP5670914B2 (ja) 2015-02-18
AU2009330245B2 (en) 2013-05-02
ES2442167T3 (es) 2014-02-10
DK2379580T3 (da) 2014-01-20
SG172299A1 (en) 2011-07-28
WO2010075215A1 (en) 2010-07-01
CY1114883T1 (el) 2016-12-14
CN102325787A (zh) 2012-01-18
KR20110114592A (ko) 2011-10-19
PL2379580T3 (pl) 2014-05-30
CA2747965A1 (en) 2010-07-01
SI2379580T1 (sl) 2014-02-28
CN102325787B (zh) 2014-05-28
US20100184649A1 (en) 2010-07-22
CA2747965C (en) 2017-06-27
EP2379580B1 (en) 2013-10-23
RU2011130278A (ru) 2013-01-27
MX2011006803A (es) 2011-09-06
US20150337013A1 (en) 2015-11-26
US20140073558A1 (en) 2014-03-13
TWI444198B (zh) 2014-07-11
BRPI0923567A2 (pt) 2016-09-27
US8507647B2 (en) 2013-08-13
RS53152B (sr) 2014-06-30
RU2512396C2 (ru) 2014-04-10
IL213638A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
NZ594019A (en) Novel antibacterial agents for the treatment of gram positive infections
GB2480773B (en) Compositions for the treatment of diarrhea caused by virulent E. coli infections
WO2010063996A3 (en) Antibacterial compounds
GB2480772A (en) Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
NZ593892A (en) Antibiotic compositions for the treatment of gram negative infections
NZ708928A (en) Mannose derivatives for treating bacterial infections
WO2011005341A3 (en) Compositions and methods related to protein a (spa) variants
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
IN2012DN01233A (enExample)
GEP20156370B (en) Fluoro-pyridinone derivatives useful as antibacterial agents
WO2010151784A3 (en) Antimicrobial compounds
MX2013000369A (es) Composiciones para el tratamiento de infecciones de pulmon, formuladas para ser administrables mediante aerolizacion, y que incluyen tobramicina.
MX2011008043A (es) Derivados de actagardina.
PH12014500317A1 (en) Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones
MX2014001599A (es) 3,4-dihidro-1h-[1,8]naftiridinosas sustituidas con piperidinilo antibacterianas.
MX2009006325A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
WO2012177075A3 (ko) 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물
MX2009009074A (es) Macrolidos basados en eritromicina.
MX2015008373A (es) Peptidos antimicrobianos, composiciones que los comprende y usos.
MX2012004282A (es) Composiciones farmaceuticas.
WO2012093859A3 (ko) 폴리사이클릭 펩타이드 화합물을 포함하는 항균용 조성물 및 이의 생산방법
WO2010086617A3 (en) Phosphoantigens for the treatment of burkholderia infections
SG178936A1 (en) Compositions and methods for treating bacterial infections using ceftaroline

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 DEC 2016 BY COMPUTER PACKAGES INC

Effective date: 20140128

ASS Change of ownership

Owner name: MERCK SHARP + DOHME CORP., US

Effective date: 20160107

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 DEC 2017 BY THOMSON REUTERS

Effective date: 20161117

LAPS Patent lapsed